{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-316820","form_type":"8-K","ticker":"MPLT","cik":"0001770069","company_name":"MapLight Therapeutics, Inc.","filed_at":"2026-07-27T11:07:27+00:00","discovered_at":"2026-07-27T11:10:00.294288+00:00","generated_at":"2026-07-27T11:10:07.401196+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MapLight reports positive Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia","bullets":["Primary endpoint met: 210/3 mg BID dose showed statistically significant PANSS total score reduction vs placebo (effect size 0.37, p=0.015, LS mean diff -4.5).","Cognitive performance improved in patients with baseline impairment (effect size 0.51, p=0.041) on prespecified secondary endpoint.","ML-007C-MA was well tolerated with no serious or drug-related severe adverse events; all-cause discontinuation low at 19.9%.","Company plans End-of-Phase 2 FDA meeting and additional confirmatory trial to support NDA submission.","Also reported positive IRIS Phase 2 results for ML-004 in autism irritability; plans FDA EOP2 meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-316820","json":"https://secwatch.observer/filing/0001193125-26-316820.json","markdown":"https://secwatch.observer/filing/0001193125-26-316820.md","text":"https://secwatch.observer/filing/0001193125-26-316820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/0001193125-26-316820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/d139086d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T11:10:07.401196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}